ACER News and Press, Acer Therapeutics Inc. From 11/14/22

NEWTON, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported fi...

Acer Therapeutics ( NASDAQ: ACER ) said the U.S. Patent and Trademark Office (USPTO) will issue a patent for claims related to certain methods of treating vascular Ehlers-Danlos syndrome (vEDS) with celiprolol. The company added that the patent application No. 16/93...

NEWTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, tod...

SWK Holdings Provides Portfolio Update Highlighting Recent Achievements PR Newswire Third Quarter 2022 Financial Results to be Announced in Early November DALLAS , Oct. 18, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...

$3 million awarded to University of North Carolina (UNC) to support a proposed 180-patient, randomized, placebo-controlled trial in trauma patients Proposed investigator sponsored trial to evaluate the potential for ACER-801 to reduce the frequency and severity of acute stress d...

Acer Therapeutics ( NASDAQ: ACER ) said on Wednesday it was expanding ACER-801 into a new indication, to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder. ( ACER ) is trading 3.5% higher premarket. In a study con...

Licensed exclusive worldwide rights from Emory University to patents and patent applications for certain methods of treating or preventing post-traumatic stress disorder (PTSD) with osanetant Osanetant targets a distinct group of brain cells in a region of the brain that control...

NEWTON, Mass. and GENEVA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief) today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance to Acer for U...

NEWTON, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced t...

Acer Therapeutics press release ( NASDAQ: ACER ): Q2 GAAP EPS of -$0.17 beats by $0.42 . Cash and cash equivalents were $14.5 million For further details see: Acer Therapeutics GAAP EPS of -$0.17 beats by $0.42